Table 1.
Demographic Characteristics of the Critically Ill Patients
| Descriptive Data | Model Establishment n or Median (Range) | Model Validation n or Median (Range) | P value |
|---|---|---|---|
| Demographic variables | |||
| Male | 117 (34/83) | 35 (9/26) | 0.783 |
| Age (years) | 62 (19–90) | 55 (28–85) | 0.343 |
| Weight (kg) | 63.0 (43.8–115.0) | 65.8 (40.0–91.0) | 0.386 |
| Height (cm) | 168 (150–183) | 169 (150–179) | 0.257 |
| BMI (kg/m2) | 21.2 (19.5–35.5) | 23.0 (17.7–31.5) | 0.344 |
| Coexisting illness/comorbidities | |||
| Diabetes mellitus | 29 (25%) | 7 (20%) | 0.596 |
| Hypertension | 46 (39%) | 17 (49%) | 0.359 |
| Hyperlipidemia | 3 (3%) | 0 (0%) | 0.234 |
| Acute renal failure | 7 (6%) | 4 (11%) | 0.424 |
| Chronic renal failure | 3 (3%) | 2 (6%) | 0.221 |
| Charlson Comorbidity Index | 2 (0–10) | 2 (0–9) | 0.638 |
| Main reason for linezolid treatment | |||
| Pneumonia | 89 (76%) | 23 (66%) | 0.511 |
| Skin and soft tissue infections | 3 (3%) | 1 (3%) | 0.832 |
| Bone and joint infections | 1 (1%) | 0 (0%) | 0.799 |
| Intra-abdominal infections | 7 (6%) | 3 (9%) | 0.653 |
| CNS infection | 5 (4%) | 1 (3%) | 0.233 |
| Bloodstream infections | 2 (2%) | 5 (14%) | 0.093 |
| Microbiological isolate | |||
| S. aureus | 5 (4%) | 5 (14%) | 0.102 |
| Enterococcus spp. | 3 (3%) | 1 (3%) | 0.846 |
| Streptococcus spp. | 2 (2%) | 2 (6%) | 0.231 |
| MRSA | 23 (20%) | 9 (26%) | 0.098 |
| Other gram-positive bacteria | 3 (3%) | 3 (9%) | 0.155 |
| Unknown | 18 (15%) | 8 (23%) | 0.632 |
| Additional antibiotics | |||
| Glycopeptides | 20 (17%) | 12 (34%) | 0.315 |
| Penicillins | 21 (18%) | 11 (31%) | 0.122 |
| Cephalosporins | 32 (27%) | 8 (23%) | 0.511 |
| Carbapenem | 58 (50%) | 18 (51%) | 0.648 |
| Macrolides | 1 (1%) | 1 (3%) | 0.833 |
| Fluoroquinolones | 18 (15%) | 5 (14%) | 0.230 |
| Aminoglycosides | 2 (2%) | 2 (6%) | 0.387 |
| Others | 10 (9%) | 2 (6%) | 0.465 |
| Linezolid therapy | |||
| Dose of linezolid | 600 mg q12h | 600 mg q12h | |
| Duration of linezolid treatment a (days) | 8 (1–27) | 9 (1–27) | 0.943 |
| Plasma Cmax of linezolid (mg/L) | 16.3 (1.4–104.0) | 17.7 (5.56–36.8) | 0.843 |
| Plasma Cmin of linezolid (mg/L) | 5.05 (0.1–33.6) | 6.44 (0.1–29.6) | 0.954 |
| Others | |||
| Serum creatine concentration (sCr, μmol/L) | 125.9 (24.9–520.6) | 117.1 (21.8–619.1) | 0.427 |
| Creatinine clearance (CrCL, mL/min) | 47.4 (8.75–222.4) | 48.8 (7.5–196.0) | 0.539 |
| Alanine aminotransferase, (ALT, U/L) | 24 (2–953) | 27 (5–3314) | 0.075 |
| Aspartate aminotransferase, (AST, U/L) | 36 (3.8–4134) | 48 (11–1849) | 0.406 |
| Total bilirubin, (TBIL, μmol/L) | 19.5 (2.7–336) | 19.2 (2.7–500.3) | 0.844 |
| Direct Bilirubin, (DBIL, μmol/L) | 5.7 (0.8–187) | 6.3 (0.8–253.2) | 0.745 |
| APACHE II baseline | 21 (10–40) | 26 (16–35) | 0.098 |
| SOFA baseline | 10 (2–18) | 8 (2–20) | 0.639 |
| CRRT mode (Yes/No) during therapy | 42/75 | 11/24 | 0.655 |
Abbreviations: BMI, body mass index; CNS, central nervous system; MRSA, methicillin-resistant Staphylococcus aureus; Cmax, the peak concentration post dose; Cmin, the trough concentration; APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; CRRT, continuous renal replacement therapy.